Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening.

OBJECTIVE To evaluate measurement of percentage of free prostate-specific antigen (PSA) in serum to improve the specificity of prostate cancer screening in men with serum PSA levels between 4.1 and 10.0 ng/mL. DESIGN Retrospective, nonrandomized analysis using a research assay for measuring free PSA in frozen serum from men with a spectrum of prostate sizes and digital rectal examination results. SETTING General community outpatient prostate cancer screening program at a university center. PATIENTS One hundred thirteen men aged 50 years or older, 99% of whom were white, with serum PSA concentrations of 4.1 to 10.0 ng/mL, including 63 men with histologically confirmed benign prostatic hyperplasia, 30 with prostate cancer with an enlarged gland, and 20 with cancer with a normal-sized gland. All study volunteers had undergone prostatic ultrasonography and biopsy. MAIN OUTCOME MEASURES Percentage of free PSA in serum and percentage of free PSA cutoff that maintained at least 90% sensitivity for prostate cancer detection. RESULTS Median percentage of free PSA was 9.2% in men with cancer and a normal-sized gland, 15.9% in men with cancer and an enlarged gland, and 18.8% in men with benign prostatic hyperplasia (P < .001). The percentage of free PSA cutoff was higher in men with an enlarged gland and in those with a palpably benign gland. In men with an enlarged, palpably benign gland, a free PSA cutoff of 23.4% or lower detected at least 90% of cancers and would have eliminated 31.3% of negative biopsies. CONCLUSIONS Measurement of percentage of free serum PSA improves specificity of prostate cancer screening in selected men with elevated total serum PSA levels and can reduce unnecessary prostate biopsies with minimal effects on the cancer detection rate; however, further studies are needed to define optimal cutoffs. Final evaluation of PSA screening also must consider the ability of current treatments to improve the prognosis of screen-detected prostate cancer.

[1]  B. Dalkin,et al.  Prostate specific antigen levels in men older than 50 years without clinical evidence of prostatic carcinoma. , 1993, The Journal of urology.

[2]  W. Catalona,et al.  Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. , 1991, The New England journal of medicine.

[3]  T. Stamey,et al.  Prostate-Specific Antigen as a Serum Marker for Adenocarcinoma of the Prostate , 1987 .

[4]  D. Hosmer,et al.  Applied Logistic Regression , 1991 .

[5]  J. Richie,et al.  Selection of optimal prostate specific antigen cutoffs for early detection of prostate cancer: receiver operating characteristic curves. , 1994, The Journal of urology.

[6]  U. Stenman,et al.  A complex between prostate-specific antigen and alpha 1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer. , 1991, Cancer research.

[7]  W. Catalona,et al.  Rate of change in serum prostate specific antigen levels as a method for prostate cancer detection. , 1994, The Journal of urology.

[8]  J. Richie,et al.  Comparison of prostate specific antigen concentration versus prostate specific antigen density in the early detection of prostate cancer: receiver operating characteristic curves. , 1994, The Journal of urology.

[9]  M. Terris,et al.  Determination of prostate volume by transrectal ultrasound. , 1991, The Journal of urology.

[10]  W. Catalona,et al.  The nature of prostate cancer detected through prostate specific antigen based screening. , 1994, The Journal of urology.

[11]  P. Walsh,et al.  Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. , 1994, JAMA.

[12]  O. Nilsson,et al.  Serum prostate specific antigen complexed to alpha 1-antichymotrypsin as an indicator of prostate cancer. , 1993, The Journal of urology.

[13]  P. Knekt,et al.  Serum concentrations of prostate specific antigen and its complex with α1-antichymotrypsin before diagnosis of prostate cancer , 1994, The Lancet.

[14]  C G Chute,et al.  Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age-specific reference ranges. , 1993, JAMA.

[15]  Nitin R. Patel,et al.  A Network Algorithm for Performing Fisher's Exact Test in r × c Contingency Tables , 1983 .

[16]  J. Oesterling,et al.  Clinical Stage B0 or T1c prostate cancer: nonpalpable disease identified by elevated serum prostate-specific antigen concentration. , 1993, Urology.

[17]  U. Stenman,et al.  Double-label time-resolved immunofluorometric assay of prostate-specific antigen and of its complex with alpha 1-antichymotrypsin. , 1993, Clinical chemistry.

[18]  R. Kane,et al.  Relative sensitivity and specificity of serum prostate specific antigen (PSA) level compared with age‐referenced PSA, PSA density, and PSA change , 1994, Cancer.

[19]  O. Nilsson,et al.  Prostate-specific antigen in serum occurs predominantly in complex with alpha 1-antichymotrypsin. , 1991, Clinical chemistry.

[20]  M. Stampfer,et al.  A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer. , 1995, JAMA.

[21]  W. Catalona,et al.  Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening. , 1993, JAMA.

[22]  W. Catalona,et al.  Serial prostatic biopsies in men with persistently elevated serum prostate specific antigen values. , 1994, The Journal of urology.

[23]  A. Pantuck,et al.  Prostate specific antigen density: a means of distinguishing benign prostatic hypertrophy and prostate cancer. , 1992, The Journal of urology.

[24]  E. Metter,et al.  Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. , 1992, JAMA.